nav-left cat-right
cat-right

Society of Toxicology Annual Meeting & ToxExp...

The SOT Annual Meeting is the largest meeting of its kind. This annual event features a broad range of scientific sessions and a thematic program that provides partici-pants with a unique opportunity to deepen their knowledge in topical areas and interact with leaders in their respective disciplines. The scientific program includes a plenary session, the MRC Lecture, symposia, work-shops, roundtable discussions, informational...

Seegene Receives US Patent for TOCE Technology

Gaithersburg, Maryland and SEOUL, Korea, November 19, 2014 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that it has been issued a United States Patent, No. 8,809,239, for its tagging oligonucleotide capture and extension (TOCE™) technology, which enables highly multiplexed target amplification and detection in a single tube. TOCE™ technology is now IP protected in...

Novavax, U. of Maryland report positive preclinica...

With the arrival of Middle East respiratory syndrome coronavirus in the U.S. and a rising death toll in Saudi Arabia, a vaccine designed by Novavax ($NVAX) and the University of Maryland has shown promise in blocking the infection in animals. In a study published in Vaccine, researchers describe a novel method to rapidly develop vaccines against previously unknown viruses, such as MERS-CoV, which emerge suddenly and cause...

Gates, Wellcome bet $40M on Kymab’s antibody...

Cambridge, U.K.’s Kymab touts its drug development platform as an ideal way to spotlight new antibodies, and some bright minds would seem to agree, as the Wellcome Trust and Bill and Melinda Gates Foundation have teamed up on a $40 million round for the biotech. Under the Series B terms, each organization will hand over $20 million to support the company’s Kymouse technology, a genetically engineered mouse...

Experimental drug could thwart measles outbreaks

A new antiviral drug may provide an effective way to treat measles in those who have not been vaccinated. When tested in an oral form in animals infected with a similar version of the measles virus, the experimental drug not only prevented animals from dying of the disease, but it significantly reduced virus levels. Developed by scientists from the Institute for Biomedical Sciences at Georgia State University, the Emory...

GlaxoSmithKline joins a $115M antibiotics developm...

Resistance to antibacterials is fast becoming one of the most urgent public health problems, especially since the pipeline for new antibiotics largely has dried up after Big Pharma’s retreat from the field in recent years. To help combat growing antimicrobial resistance, more than 30 European universities, research institutions and drug companies are joining together to launch a 6-year, €85 million ($115.5 million)...
Page 2 of 712345...Last »